Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407296 | 1.00 | SLC7A5 (0.50) | SLC7A5HDAC8ITGB3ITGA2BTAAR1 | |
| SCHEMBL13416262 | 0.99 | SLC7A5 (0.49) | SLC7A5HDAC8ITGB3ITGA2BTAAR1 | |
| SCHEMBL13416627 | 0.97 | SLC7A5 (0.50) | SLC7A5HDAC8ITGB3ITGA2BTAAR1 | |
| SCHEMBL16607621 | 0.88 | SLC7A5 (0.59) | SLC7A5HDAC8ITGB3ITGA2BTAAR1 | |
| SCHEMBL13416629 | 0.88 | SLC7A5 (0.49) | SLC7A5HDAC8TAAR1SLC6A2ESR1 | |
| SCHEMBL12846533 | 0.87 | ALPI (0.50) | SLC7A5HDAC8ITGB3ITGA2B | |
| SCHEMBL13416633 | 0.85 | SLC7A5 (0.47) | SLC7A5HDAC8TAAR1SLC6A2ESR1 | |
| SCHEMBL13416263 | 0.84 | SLC7A5 (0.41) | SLC7A5HDAC8ITGB3ITGA2BTAAR1 | |
| SCHEMBL17738628 | 0.83 | SLC7A5 (0.65) | SLC7A5HDAC8TAAR1SLC6A2ESR1 | |
| SCHEMBL13416628 | 0.83 | SLC7A5 (0.53) | SLC7A5HDAC8TAAR1SLC6A2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130375-A1 | NEW NO-RELEASING STEROIDS FOR THE TREATMENT OF RETINA AND MACULA LUTEA DISEASES | NICOX S.A. (FR) | 2011-06-02 | — | — | US | disclosed |
| WO-2010015528-A1 | NEW NO-RELEASING STEROIDS FOR THE TREATMENT OF RETINA AND MACULA LUTEA DISEASES | NICOX S.A. (FR) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130375-A1 | NEW NO-RELEASING STEROIDS FOR THE TREATMENT OF RETINA AND MACULA LUTEA DISEASES | LHCGR, NR5A1, LSS | SLC7A5 868/4885HDAC8 4595/4885ITGB3 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.